STOPMIGREN SUMATRIPTANUM tablets 50mg №6

STOPMIGREN SUMATRIPTANUM tablets 50mg №6

Product Code: 6963
Availability: In Stock
$21.40USD
-+

Ask a question about this product

Composition

active substance:sumatriptan;

50 mg tablets:

1 tablet contains sumatriptan succinate 70mg, equivalent to sumatriptan 50mg

excipients:lactose, magnesium stearate, sodium croscarmellose, cellulose microcrystalline, talc, silicon colloidal dioxide

shell:mixture for Opadry II Pink film coating (aluminium varnishes charming red (E 129) and Indigo (E 132), hypromellose, lactose, triacetin, polyethylene glycol, titanium dioxide (E 171));

100 mg tablets:

1 tablet contains sumatriptan succinate 140mg, equivalent to sumatriptan 100mg

excipients:lactose, magnesium stearate, sodium croscarmellose, cellulose microcrystalline, talc, silicon colloidal dioxide

shell:mixture for Opadry II Orange film coating (aluminium varnishes yellow sunset FCF (e 110) and Indigo (E 132), hypromellose, lactose, triacetin, polyethylene glycol, iron oxide yellow (E172), titanium dioxide (E 171)) .

The

Dosage form

Tablet, film-coated.

basic physico-chemical properties:

50 mg tablets:

tablets are round in shape with a concave surface, film-coated pink

100 mg tablets:

tablets are round in shape with a concave surface, film-coated orange.

The

drug description

drugs used to treat migraine. Selective agonists 5НТ1serotonin receptor. ATC code C01 N02С.

The

Pharmacological properties

Pharmacodynamics.

Sumatriptan is a selective agonist OF 5NT1receptors, which does not affectother 5NT receptors. These receptors are found mainly in cranial blood vessels. In the course of experimental studies, it was found that sumatriptan has a selective vasoconstrictor effect on blood vessels in the carotid artery system, but does not affect cerebral circulation. The system of the carotid arteries supplying blood to the extra-and intracranial tissues, such as meninges. Due to the widening of these blood vessels develops a migraine. In addition, with the help of experimental data, it was proved that sumatriptan inhibits the activity of the trigeminal nerve. Are two possible mechanisms through which is ANTIMIGRAINE activity of sumatriptan.

the Clinical effect is observed 30 minutes after ingestion of 100 mg of the drug.

Pharmacokinetics.

After intake of sumatriptan is rapidly absorbed, reaching 70% of maximum concentration 45 min After ingestion of 100 mg the average maximum concentration in plasma is 45 ng/ml. Bioavailability after oral administration is 14% partly due to presystemic metabolism, partly as the result of incomplete absorption. The plasma protein binding is low (14-21%), mean volume of distribution is 17 l Average total clearance is approximately 1160 ml/min, and the average kidney klirens - 260 ml/min. Vnepochechny clearance is approximately 80% of total clearance; this gives reason to believe that sumatriptan is excreted mainly as metabolites. The major metabolite, indolite analogue of sumatriptan, is excreted in the urine, where it is provided in the form of the free acid and conjugate connections glucuronide. It does not exhibit 5NT1- and 5NT2-activity. Other metabolites are identified. Pharmacokinetics of oral sumatriptan does not significantly change during a migraine attack.

Reading

Pills Stopmacro prescribed for quick relief of a condition with attacks of migraine, with aura or without it.

Contra

Hypersensitivity to the components of the drug.

myocardial Infarction a history of coronary heart disease, Prinzmetal's angina, peripheral vascular disease or symptoms of coronary heart disease.

Stroke or transient disorders of cerebral circulation in the anamnesis.

Moderate to severe hypertension and mild uncontrolled hypertension.

Severe hepatic insufficiency.

concomitant use of ergotamine or derivatives (including methysergide) (see Section "Interaction with other medicinal products and other forms of interaction").

Concurrent use of any of triptone agonist/5-hydroxytryptamine receptors (5-HT1) (see Section "Interaction with other medicinal products and other forms of interaction").

Competitive use of Mao (MAO) and stop Migraine inhibitors. Stop migraine should not be used within 2 weeks after the removal of MAO inhibitors.

Special safety precautions

Pills Stopmacro used only when clearly established diagnosis of migraine.

stop migraine Is not used for the treatment of hemiplegic, basilar and ophthalmoplegic migraine. As with other drugs, for relief of migraine attacks in patients with a previously unknown diagnosis of migraine and in patients with an established diagnosis, but in the presence of atypical symptoms, before taking sumatriptan, the presence of another serious neurological pathology should be excluded. It should be noted that patients with migraine have an increased risk of cerebrovascular disorders (stroke, transient cerebral circulation disorder).

the Use of sumatriptan in some patients may cause such temporary symptoms as pain, feeling of compression in the chest, which can be intense and spread to the larynx (see Section "Adverse reactions"). If such symptoms indicate ischemic heart disease, appropriate cardiac examination should be carried out.

sumatriptan Should not be administered to patients suspected of heart disease without a preliminary examination to detect cardiovascular disease. To this group of patients include women in post-menopausal, men aged 40 years and patients with risk factors of coronary heart disease. However, such examination may not always reveal the presence of heart disease, so in rare cases in patients with undiagnosed heart disease there are severe cardiac complications. Stopmacro should be administered with caution to patients who are under observation on arterial hypertension, as a small number of patients may experience a transient increase in blood pressure and peripheral vascular resistance.

Described isolated cases of serotonin syndrome (including altered mental status, visceral instability, neuromuscular disorders) that occurred after administration of selective inhibitors of serotonin reuptake (SSRI) and sumatriptan. There are reports of the development of serotonin syndrome with the simultaneous appointment of tryptans and serotonin reuptake inhibitors and noradrenaline (SNRI). If the simultaneous use of Stopmacro and SSRI/SNRI is clinically warranted, it is desirable to have a preliminary examination of patients (see Section "Interaction with other medicinal products and other forms of interaction").

it is not recommended to use sumatriptan simultaneously with any tryptans/5NT1agonist.

stop Migraine should be used with caution in patients with significant disorders of absorption, metabolism or withdrawal of drugs, such as renal and hepatic insufficiency.

stop Migraine should be used with caution in patients with history of convulsions or risk factors that reduce the threshold of convulsive readiness.

in patients with hypersensitivity to sulfonamides may experience allergic reaction after application Stormygrey. Reactions may occur in the range of skin hypersensitivity to anaphylaxis. The occurrence of cross-sensitivity is unlikely, but caution should be exercised when prescribing the drug to such patients.

the Recommended dose Stormygrey cannot be exceeded.

Intensive care for acute migraine attacks is associated with exacerbation of headache (headache caused by intensive care) in sensitive patients. Termination of treatment may be required.

Adverse reactions may occur more frequently during co-administration of tryptans and herbal preparations containing St. John's wort(Hypericum perforatum).

Prolonged use of any type of painkillers may increase headache. In the event of such a situation or the threat of its occurrence, you should consult your doctor and stop. In patients who often or every day there is a headache due to the regular use of medicines against headache, can be diagnosed headache due to the abuse of painkillers. 

the Drug contains lactose, so patients with rare hereditary forms of galactose intolerance, lactose deficiency or glucose-galactose malabsorption syndrome should not use the drug.

Interaction with other medicinal products and other forms of interaction.

there is No data on the interaction with propranolol, flunarizine, pizotifen or alcohol.

data on co-administration with medicines containing ergotamine or other triptane agonists/5-HT1receptors are limited. Theoretically, prolonged vasospastic reactions are possible, so such joint use is contraindicated (see section "Contraindications").

Temporary the interval that should be observed between doses of sumatriptan and medicines containing ergotamine or other agonists of triptone/5-HT1receptors is unknown. It depends on the doses and type of medicines used. Since these effects can be enhanced by taking stop Migraine, it is necessary to observe a 24-hour interval between taking drugs containing ergotamine and other triptane agonists/5-HT1- receptors, and taking stop Migraine. Accordingly, preparations containing ergotamine and other agonists by triptone/5-HT1receptors, it is impossible to apply for 6:00 after taking Stormygrey.

the Interaction may occur between sumatriptan and MAO inhibitors, so their simultaneous use is contraindicated (see "Contraindications").

There are a few post-marketing reports of patients developing serotonin syndrome (including altered mental status, visceral instability, neuromuscular disorders) after administration of selective inhibitors of serotonin reuptake (SSRI) and sumatriptan. There are reports of the development of serotonin syndrome with the simultaneous use of tryptans and serotonin reuptake inhibitors and noradrenaline (SNRI) (see "application Features").

application Features

use during pregnancy or lactation.

the ratio of the expected benefit to the mother and the risk to the fetus should be weighed.

to apply caution in breast feeding period. It is not recommended to breastfeed the baby within 24 hours after taking the drug.

Ability to influence the reaction rate when driving motor transport or operating other mechanisms.

the Sleepiness can be a consequence of migraine and its treatment Stoperror, so you should avoid driving vehicles or operating other mechanisms.

Method of application and doses

Pills Stopmacro can not be applied to prevent attack.

stop Migraine is recommended as soon as possible after the onset of a migraine attack, although it is still effective at each stage.

Stormygrey the recommended dose for adults is 50 mg. In some cases, the dose can be increased to 100 mg.

if the dose is ineffective, do not use another dose during the same attack. Another dose of stop Migraine can be used in the following attacks.

if the patient reacts to the first dose, but the symptoms resume, the second dose can be applied within 24 hours, with the total dose during the day should not exceed 300 mg.

the Tablets should be swallowed whole, with water.

elderly Patients (over 65 years).

Experience in the use of sumatriptan in patients over 65 years is not enough. Although the pharmacokinetics of the drug in the elderly does not differ from that in persons of younger age, destination Stormygrey elderly patients is not recommended.

Children.is not recommended, as the efficacy and safety of sumatriptan in children have not been established by this time.

Overdose

Doses exceeding 400 mg (orally) did not take any side effects other than those listed below.

in case of overdose it is necessary to monitor the patient for at least 10:00 and the usual supportive activities.

the effect of hemodialysis or peritoneal dialysis on plasma stop Migraine levels has not been established. 

Side effects

from the nervous system:dizziness, drowsiness, impaired sensitivity (including paresthesia and hypesthesia) convulsions (although some of these cases were noted in patients with convulsions or conditions that may lead to them, in history, cases of convulsions in patients without any tendency to them); tremor, dystonia, nystagmus, scotoma.

from the cardiovascular system:transient increase in blood pressure immediately after taking the drug, blood flow bradycardia, tachycardia, increased heartbeat, rhythm disturbances, transient ischemic changes on ECG, spasm of coronary arteries, angina pectoris, myocardial infarction, arterial hypotension, Raynaud's disease.

from the respiratory system:shortness of breath.

From the digestive system:nausea and vomiting that occurs in some patients, but their relationship with the use of Stopmacro not been fully elucidated; ischemic colitis, diarrhea.

from the musculoskeletal system and connective tissue:feeling of heaviness, myalgia rigidity of the neck muscles, arthralgia.

the above symptoms are usually transient, may be intense and affect any part of the body, including the chest and throat.

Allergic reactions:hypersensitivity reactions - from skin hypersensitivity to cases of anaphylaxis.

on the part of the visual organs:flicker in the eyes, diplopia, reduced visual acuity; loss of vision (usually transient). However, visual impairment can be a consequence of the migraine attack itself.

General disorders:pain, feeling warm or cold, compression or tension (usually transient, can be intense and affect any part of the body, including chest and throat) feeling of weakness, fatigue (mainly mild or moderate and are transient).

Laboratory data:, there were minor changes in liver function tests.

Mental disorders:excitement.

on the part of the skin and subcutaneous tissue:hyperhidrosis.

The

shelf Life

3 years.

storage Conditions

Store in its original packaging at a temperature not exceeding 25 ° C.

keep out of reach of children.

The

Packaging

Tablets of 50 mg.of 6 tablets in a blister, 1 blister pack.

Tablets of 100 mg.of 3 tablets in a blister, 1 blister pack.

The

Category vacation

According to the recipe.

The

Manufacturer

PJSC "Kyiv vitamin factory".

location of the manufacturer and address of the place of business

04073, Ukraine, G.. Kyiv, Kopylivska, 38.

Web-site: www.vitamin.com.ua.

MIGRANAL TABLETS 50MG

Migranal tablets 50 mg №10 with an active the active ingredient with the sumatriptan. The drug is a selective agonist of serotonin receptors 5NT1. It is used for effective treatment of migraines. Quickly eases the condition in migraine attacks with aura and without. Therapeutic activity manifests itself:

  • Vasoconstricting effect, relief of headache.
  • Delayed release of anti-inflammatory neuropeptides. 
  • The
  • Activation of receptors 5НТ1 localized in the blood vessels of the brain.

Relief the condition is observed half an hour after taking the drug. Migranal does not apply to prevent the attack.

the Use, contraindications 

the Tool is designed for oral use. The minimum dose of sumatriptan – 20 mg. possible the single norm of 100 mg. If the dose was ineffective, re-admission is possible only after 24 hours. The drug is contraindicated in uncontrolled hypertension, severe renal and hepatic failure, ischemic heart disease, myocardial infarct in anamnesis, pregnancy. Pills are not assigned concurrently with MAO inhibitors, pizotifen, propranolol. It is not recommended to combine with alcohol. 

Write a review

Note: HTML is not translated!
    Bad           Good

Recently viewed

Pharmacy03.com © 2019